ClinicalTrials.gg
RecruitingNCT07287878Updated Dec 24, 2025

Neural Mechanisms of Temporal Interference Stimulation on Improving Social Reward Function in Depression

An interventional study of Temporal Interference Simulation(TIS) and Temporal Interference Stimulation(TIS) in Depression, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 16 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Depression by Shanghai Mental Health Center — 3 open to participants now, 5 under way, none of them phase 3. Depression · Shanghai Mental Health Center.

Planned enrollment
6th of 11
120 · median 120
Started
2025
with 1 other
No phase
6 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Depression by Shanghai Mental Health Center, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 with no phase, and was the 14th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

3 of the 15 studies in Depression by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Depression by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

Major depressive disorder (MDD) is a mood disorder characterized primarily by low mood, diminished interest, and reduced energy. Traditional views considered depression a non-degenerative condition; however, recent epidemiological studies have revealed its significant association with impaired social functioning. Data indicate that 59.3% of patients with depression experience social dysfunction of varying severity [1], particularly manifesting as difficulties in social interaction and relationship maintenance [2]. Therefore, investigating the mechanisms underlying social dysfunction is of great importance for promoting functional recovery in MDD, and dysfunction within the social reward system may represent a core factor, though the specific neural mechanisms remain unclear.

The ultimate goal of understanding the neural mechanisms underlying social reward impairment in depressed patients is to improve therapeutic outcomes. Temporal Interference (TI) stimulation, as a non-invasive deep brain stimulation technique, utilizes high-frequency current differentials to generate low-frequency amplitude-modulated electric fields, enabling precise targeting of deep brain regions. This study employs multimodal assessment methods-such as functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and specific cognitive-behavioral tasks-combined with TI stimulation to observe immediate changes in functional connectivity, neural activity, and related cognitive functions (e.g., decision-making, memory) across participant groups. The research aims to elucidate the roles of the parahippocampal gyrus, orbitofrontal cortex, and striatum in social reward impairment in depression, and to explore circuit-based intervention targets, thereby providing novel strategies for the recovery of social functioning in MDD.

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16-60 years old;
  • Meeting with the criteria of major depressive disorder in the (DSM)-5;
  • Scored 20 or higher on the Hamilton's Depression Scale with 24 items (HAMD-24);
  • With enough audio-visual ability and comprehensive ability to accomplish the visits;
  • Be necessary and suitable to accept the treatment of antidepressants;
  • Scored less than 14 on Hamilton's Anxiety Scale (HAMA) and scored less than 14 on the Hypomania Symptom Checklist-32 (HCL-32);
  • With 2 or more atypical symptoms including significant weight gain or increase in appetite, hypersomnia, leaden paralysis, and a long-standing pattern of interpersonal rejection sensitivity that results in significant social or occupational impairment.

Exclusion criteria

Exclusion Criteria:

  • Severe medical or neurological problems;
  • Previous mania or hypomania episodes;
  • Female patients who are pregnant, planning to be pregnant or breastfeeding;
  • Actively suicide ascertained by research psychiatrist or 3rd item of HAMD scored≥3(suicidality);
  • Had ECT, MECT or rTMS in the past 6 months;
  • Experienced severe personality disorder, mental retardation, anorexia/ bulimia nervosa.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    orbitofrontal cortex

    Device: Temporal Interference Simulation(TIS)

  • Experimental
    parahippocampal gyrus

    Device: Temporal Interference Simulation(TIS)

  • Experimental
    striatum

    Device: Temporal Interference Simulation(TIS)

  • Sham comparator
    sham

    Device: Temporal Interference Stimulation(TIS)

Interventions

  • DeviceTemporal Interference Simulation(TIS)

    the total stimulation duration was 20 minutes, including a 40-second current ramp-up at the beginning and a 40-second ramp-down at the end.

  • DeviceTemporal Interference Stimulation(TIS)

    Sham stimulation has only 40 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation to simulate the sensation of actual stimulation.

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Depression Rating Scale (HAMD) Score

    The HAMD is a clinical depression assessment and consists of 17 items with a total score range from 0 to 54.A higher score indicates a worse outcome.

    Time frame: baseline and immediately after the intervention

  2. Change in The Positive and Negative Affect Schedule (PANAS) Score

    The Positive and Negative Affect Schedule (PANAS) is an assessment of participants' immediate affective states and consists of 20 items divided into two subscales (10 items for Positive Affect and 10 items for Negative Affect), with each item rated on a 5-point scale; higher scores on the Positive Affect subscale indicate more positive emotional states, while higher scores on the Negative Affect subscale indicate more negative emotional states.

    Time frame: Baseline and immediately after the intervention

Secondary outcomes

  1. MRI measures

    The functional connectivity between stimulated target and the whole brain areas

    Time frame: Baseline and immediately after the intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2026, 5 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 5 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Dec 17, 2025
StartActual
Nov 15, 2025
Primary completionEst.
May 10, 2026
CompletionEst.
Jul 10, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07287878
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Nov 15, 2025
Primary completion
May 10, 2026 (estimated)
Completion
Jul 10, 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

daihui Peng, MD. PhD.
Contact
pdhsh@126.com
18017311136

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion